Fucoidan Extract Enhances the Anti-Cancer Activity of Chemotherapeutic Agents in MDA-MB-231 and MCF-7 Breast Cancer Cells
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Fucoidan, a fucose-rich polysaccharide isolated from brown alga, is currently under investigation as a new anti-cancer compound. In the present study, fucoidan extract (FE) from Cladosiphon navae-caledoniae Kylin was prepared by enzymatic digestion. We investigated whether a combination of FE with cisplatin, tamoxifen or paclitaxel had the potential to improve the therapeutic efficacy of cancer treatment. These co-treatments significantly induced cell growth inhibition, apoptosis, as well as cell cycle modifications in MDA-MB-231 and MCF-7 cells. FE enhanced apoptosis in cancer cells that responded to treatment with three chemotherapeutic drugs with downregulation of the anti-apoptotic proteins Bcl-xL and Mcl-1. The combination treatments led to an obvious decrease in the phosphorylation of ERK and Akt in MDA-MB-231 cells, but increased the phosphorylation of ERK in MCF-7 cells. In addition, we observed that combination treatments enhanced intracellular ROS levels and reduced glutathione (GSH) levels in breast cancer cells, suggesting that induction of oxidative stress was an important event in the cell death induced by the combination treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Florea, A.-M., & Büsselberg, D. (2011) · Cancers · doi:10.3390/cancers3011351 · Cited by 1,759
Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities
Koyanagi, S., Tanigawa, N., Nakagawa, H., Soeda, S., & Shimeno, H. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01478-8 · Cited by 479
Aisa, Y., Miyakawa, Y., Nakazato, T., Shibata, H., Saito, K., Ikeda, Y., & Kizaki, M. (2005) · American Journal of Hematology · doi:10.1002/ajh.20182 · Cited by 307
Alekseyenko, T. V., Zhanayeva, S. Y., Venediktova, A. A., Zvyagintseva, T. N., Kuznetsova, T. A., Besednova, N. N., & Korolenko, T. A. (2007) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-007-0226-4 · Cited by 244
Zhang, Z., Teruya, K., Eto, H., & Shirahata, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027441 · Cited by 167 · cited 6×
“We previously found that ROS is involved in mitochondria dysfunction in FE-treated MCF-7 cells [8].”
BackgroundMethodResultSelf-citationApoptosis inducing activity of fucoidan in HCT-15 colon carcinoma cells
Hyun, J.-H., Kim, S.-C., Kang, J.-I., Kim, M.-K., Boo, H.-J., Kwon, J.-M., Koh, Y.-S., Hyun, J.-W., Park, D.-B., Yoo, E.-S., et al. (2009) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.32.1760 · Cited by 150 · cited 2×
“ERK activation induced by fucoidan has been shown to contribute to the signal transduction pathways leading to cell apoptosis [4,6,15].”
BackgroundYe, J., Li, Y., Teruya, K., Katakura, Y., Ichikawa, A., Eto, H., Hosoi, M., Hosoi, M., Nishimoto, S., & Shirahata, S. (2005) · Cytotechnology · doi:10.1007/s10616-005-3761-8 · Cited by 146
Self-citationIKEGUCHI, M., YAMAMOTO, M., ARAI, Y., MAETA, Y., ASHIDA, K., KATANO, K., MIKI, Y., & KIMURA, T. (2011) · Oncology Letters · doi:10.3892/ol.2011.254 · Cited by 113 · cited 2×
“The survival of patients with fucoidan treatment was longer than that of patients without fucoidan treatment, although the difference was not significant [16].”
BackgroundLee, N. Y., Ermakova, S. P., Zvyagintseva, T. N., Kang, K. W., Dong, Z., & Choi, H. S. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.01.025 · Cited by 75
Cited by
Therapies from Fucoidan: An Update
Fitton, J., Stringer, D., & Karpiniec, S. (2015) · Marine Drugs · doi:10.3390/md13095920 · Cited by 418
“, using Cladosiphon fucoidan fractions, showed synergistic effects with three chemotherapy agents in two breast cancer cell lines [63].”
MethodFucoidan and Cancer: A Multifunctional Molecule with Anti-Tumor Potential
Atashrazm, F., Lowenthal, R., Woods, G., Holloway, A., & Dickinson, J. (2015) · Marine Drugs · doi:10.3390/md13042327 · Cited by 358
Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms
Van Weelden, G., Bobiński, M., Okła, K., Van Weelden, W. J., Romano, A., & Pijnenborg, J. M. A. (2019) · Marine Drugs · doi:10.3390/md17010032 · Cited by 330
Kumar, B. R., Mathimani, T., Sudhakar, M. P., Rajendran, K., Nizami, A.-S., Brindhadevi, K., & Pugazhendhi, A. (2021) · Renewable and Sustainable Energy Reviews · doi:10.1016/j.rser.2020.110649 · Cited by 208
Tsai, H.-L., Tai, C.-J., Huang, C.-W., Chang, F.-R., & Wang, J.-Y. (2017) · Marine Drugs · doi:10.3390/md15040122 · Cited by 156
Hsu, H.-Y., Lin, T.-Y., Hu, C.-H., Shu, D. T. F., & Lu, M.-K. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.006 · Cited by 116
Matin, M., Koszarska, M., Atanasov, A. G., Król-Szmajda, K., Jóźwik, A., Stelmasiak, A., & Hejna, M. (2024) · Molecules · doi:10.3390/molecules29194695 · Cited by 104
Singh, S., Verma, D. K., Thakur, M., Tripathy, S., Patel, A. R., Shah, N., Utama, G. L., Srivastav, P. P., Benavente-Valdés, J. R., Chávez-González, M. L., et al. (2021) · Food Research International · doi:10.1016/j.foodres.2021.110746 · Cited by 98
Metadata
- Authors
- Zhang, Z., Teruya, K., Yoshida, T., Eto, H., & Shirahata, S.
- Venue
- Marine Drugs
- Publisher
- MDPI AG
- Published
- 2013-01-09
- Volume
- 11
- Issue
- 1
- Pages
- 81-98
- ISSN
- 1660-3397 (ISSN-L)
- OpenAlex
- W2014297192
- Cited by
- 150
- References
- 10
- FWCI
- 16.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.